BioHealth News

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants…

Read More
Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications

Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications

FREDERICK, Md., Dec. 10, 2024 /PRNewswire/ -- Theradaptive, a privately held, clinical stage biologics company developing protein therapeutics for spine, orthopedics, soft tissue repair, and targeted…

Read More
BHI at TEDCO’s 10th Entrepreneur Expo: A Celebration of Maryland’s Innovation Ecosystem

BHI at TEDCO’s 10th Entrepreneur Expo: A Celebration of Maryland’s Innovation Ecosystem

On December 4th, TEDCO hosted its 10th Entrepreneur Expo in Baltimore, bringing together over 1,000 entrepreneurs, investors, and industry leaders for a day of…

Read More
NextCure Secures FDA IND Approval to Launch Phase 1 Trial of LNCB74 Antibody-Drug Conjugate for Cancer

NextCure Secures FDA IND Approval to Launch Phase 1 Trial of LNCB74 Antibody-Drug Conjugate for Cancer

BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies…

Read More
Annapolis’ Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

Annapolis’ Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ --  Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office (USPTO) has…

Read More
Frederick’s Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery

Frederick’s Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery

Multiplexed, extraction-free, full-length library preparation technology facilitates large-scale RNA sequencing, combining ever more content with high throughput FREDERICK, Md., Dec. 9, 2024 /PRNewswire-PRWeb/ -- Alithea Genomics,…

Read More
FY25 MBIA Commercialization Innovation Grant Applications Open December 10

FY25 MBIA Commercialization Innovation Grant Applications Open December 10

The Maryland Business Innovation Association (MBIA), with support from TEDCO, has announced the launch of the FY25 MBIA Commercialization Innovation Grant (MCIG). Designed to…

Read More
BDC and Maryland Department of Commerce Announce Board of Estimates Approval of Conditional Loan for 4MLK Flex Lab Space

BDC and Maryland Department of Commerce Announce Board of Estimates Approval of Conditional Loan for 4MLK Flex Lab Space

Baltimore, MD—The Baltimore Development Corporation (BDC) and the Maryland Department of Commerce are pleased to announce the Baltimore City Board of Estimates' approval of…

Read More
Children’s National, FDA collaborate to advance pediatric device regulatory tools

Children’s National, FDA collaborate to advance pediatric device regulatory tools

WASHINGTON (Dec. 4, 2024) — In a significant collaboration to help advance pediatric health, Children’s National Hospital and the U.S. Food and Drug Administration’s…

Read More
Advancing MRI Metabolic Imaging: Join NCI’s Upcoming Technology Opportunity Webinar

Advancing MRI Metabolic Imaging: Join NCI’s Upcoming Technology Opportunity Webinar

The National Cancer Institute (NCI) Technology Transfer Center is hosting a webinar on an exciting new technology that could revolutionize MRI metabolic imaging. Scheduled…

Read More
Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis and Previews Phase 3 Trial

Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis and Previews Phase 3 Trial

FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for…

Read More
Gaithersburg’s Shuttle Pharma Begins Phase 2 Trial of Ropidoxuridine for Glioblastoma at UVA Cancer Center

Gaithersburg’s Shuttle Pharma Begins Phase 2 Trial of Ropidoxuridine for Glioblastoma at UVA Cancer Center

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company…

Read More
Revolutionizing Respiratory Care: Linshom Medical’s Journey to Innovation and Recognition on BioTalk

Revolutionizing Respiratory Care: Linshom Medical’s Journey to Innovation and Recognition on BioTalk

[vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" column_element_spacing="default" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none"…

Read More
University of Maryland Institute for Health Computing Celebrates Second Anniversary

University of Maryland Institute for Health Computing Celebrates Second Anniversary

Uncovering bias in AI models used in medical diagnosis. Identifying patients with potentially life-threatening antibiotic-resistant infections. Predicting the spread of disease with advanced computing.…

Read More
Arlington Capital Partners Acquires TEAM Technologies

Arlington Capital Partners Acquires TEAM Technologies

Washington, D.C. – November 25, 2024 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it…

Read More